Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Report from Concentric AB’s annual general meeting on April 18, 2024

Concentric AB’s annual general meeting was held on Thursday, April 18, 2024. The main resolutions passed were the following. Regarding full details of the resolutions, referral is made to the notice convening the AGM and the complete proposals. The notice convening the AGM and the complete proposals are available at the company’s website, www.concentricab.com. Adoption of the income statements and the balance sheets The general meeting resolved to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet for the financial year

Invitation to Kongsberg Automotive's Q1 2024 Earnings call

Zurich, April 18, 2024: Kongsberg Automotive (KA) will release its Q1 results on Wednesday May 8, 2024 at approximately 07:00 CET. President & CEO Linda Nyquist-Evenrud and CFO Frank Heffter will present the results during a webcast at 09:00 CET and will host a Q&A session after the presentation. The event is open to the public and will be webcasted live. The following link:https://channel.royalcast.com/landingpage/hegnarmedia/20240508_7/ 

Resolutions of the Annual General Meeting of Kamux Corporation and the Decisions of the Constitutive Meeting of the Board of Directors

Kamux Corporation, Stock Exchange Release, 18.4.2024 at 16:00 Resolutions of the Annual General Meeting of Kamux Corporation and the Decisions of the Constitutive Meeting of the Board of Directors Kamux Corporation’s Annual General Meeting was held on Thursday, April 18, 2024. The Meeting approved the Annual Accounts for the financial year 2023 and discharged the members of the Board of Directors and the CEO from liability and made an advisory resolution to approve the remuneration report and remuneration policy for the governing bodies. Payment of dividend In accordance with

BEWI ASA publishes annual report for 2023

BEWI, a leading provider of packaging, components, and insulation solutions, today publishes its annual report for the financial year of 2023. The annual report was approved by the board of directors of BEWI on 17 April 2024 without any changes to the preliminary accounts for the full year 2023 announced on 15 February 2024. In the letter to the stakeholders, the chair of the board Gunnar Syvertsen, and CEO Christian Bekken comments: “2023 was a year marked by the consequences of wars and macroeconomic uncertainty following the measures to curb the effects of inflation and rising

Snowmobiles now in use 365 days in a year

The expert for charging solutions InterControl Oy and the manufacturer of electric snowmobiles Aurora Powertrains Oy are presenting the first bidirectional charging for snowmobiles. The both companies from Finland were at Nordic EV Summit in Oslo in April 2024 with this truly electrifying solution for the mobile environment.    ”Electric snowmobiles are entering the market with a significant speed. eSled Aurora is not producing any CO2- or other emissions, it is odourless and quiet and do not disturb other people in the nature. Stable and agile behaviour in driving is also appreciated

Olvi plc: Notification of Managers’ Transactions

Olvi plc                              Stock Exchange Release 18 April 2024 at 3.30 pm Olvi plc: Notification of Managers’ Transactions Person subject to the notification requirementName: Liukkonen Tiina-LiisaPosition: Chief Financial OfficerIssuerName: Olvi plcLEI: 7437003NX7WWVRT6AJ55Initial notificationReference number: 58860/5/4 Transaction detailsTransaction date: 17.4.2024Venue: Outside a trading venueNature of transaction: Receipt of a share-based incentiveInstrument: ShareISIN: FI0009900401Volume: 650 Unit price: 0 EUR Aggregated transactions

DOF Group ASA – Approval of the Annual Accounts 2023

The Board of Directors has today approved DOF Group ASA Integrated Annual Report 2023. The General Meeting is scheduled for Thursday 23rd of May 2024 in accordance with the financial calendar. Notice of General Meeting and the agenda with attachments will be published through Oslo Børs and www.dof.com. The Notice of General Meeting will be sent by post to shareholders who have not given explicit consent for electronic communication of notices. For further information please contact: Mons S. Aase, CEO, Tel: +47 91 66 10 12 Hilde Drønen, CFO, Tel: + 47 91 66 10 09

Invitation – presentation of Ework Group’s interim report for January - March 2024

Ework Group AB (publ) hereby invites investors, analysts, and the media to a presentation of the company’s interim report for the first quarter 2024 via webcast or telephone.Time: Thursday May 2nd at 13:00 CEST To participate: If you wish to participate via webcast, please use the link below when the broadcast starts. No registration in advance is needed. Via the webcast you can ask written questions.https://ir.financialhearings.com/ework-group-q1-report-2024/register If you wish to participate via teleconference, please register on the link below. After registration you will be

JACK & JONES and SPINNOVA takes next step in their joint development collaboration and release 2nd product made with SPINNOVA® fibre

The JACK & JONES  t-shirt is the first commercially available product made with fibre from Spinnova and Suzano‘s joint venture Woodspin’s facility, opened in 2023. It comes in three different colours, bright white, butter cream and black – each with a unique floral backprint. The shirt is made from a blend of 30% wood-based SPINNOVA®  fibre, 45% cotton, 20% organic cotton, and 5% elastane. JACK & JONES previously launched a pair of men’s trousers made with SPINNOVA® fibre in October 2022.The new t-shirt is the

SONY signs 9-year office and lab lease in Brussels

Altaal has signed a 9-year lease contract with SONY at its office and lab property, Omega Court in Brussels. The lease comprises lab space of approximately 1,250 sqm as well as an additional 1,230 sqm office space.Altaal acquired Omega Court in 2022 held to a high standard, the transformation plan for Omega Court includes achieving BREEAM Excellent certification by implementing geothermal heating, integrating energy-efficient lighting, and establishing water use monitoring. Leasable area spans almost 18,000 sqm over six floors above-ground in three wings, along with 200 parking spots below

Invitation to Fractal Gaming Group’s interim report for the first quarter of 2024

Fractal Gaming Group AB will publish its interim report for the period of January-March 2024, Thursday, April 25, 2024, at 08.00 (CEST).   In conjunction to this, a telephone and web conference will be organized for investors, analysts and media on the same day at 11.00 (CEST). CEO, Jonas Holst, and CFO, Karin Ingemarson will present and comment on the report and the conference will be followed by a question-and-answer session.   Link to web conference: https://ir.financialhearings.com/fractal-gaming-group-q1-report-2024   To sign up for the telephone conference:https:

Rugvista Group AB (publ) – publishes Annual and Sustainability Reports for January–December 2023

The Board and CEO hereby present the 2023 Annual and Sustainability Reports for Rugvista Group AB (publ). The Annual Report for 2023 includes the company’s Sustainability Report and the Corporate Governance Report. The reports will be available on the company’s website as of today: www.rugvistagroup.com/en/investors/reports-and-presentations/. Contact information Michael Lindskog, CEOMichael.Lindskog@rugvista.com Joakim Tuvner, CFOJoakim.Tuvner@rugvista.comInvestorRelations@rugvistagroup.com Certified advisor FNCA Sweden ABBox 5216Nybrogatan 34SE 102 45

Arjo’s interim report January-March 2024

”We start the year with growth and improved profitability. Rental and service develop well globally and the positive trend in the US continues, with a gradual improvement of the market situation. Overall, a solid start to the year and I look forward to continue the work together with the team to strengthen Arjo’s positions in 2024,” says Joacim Lindoff, President and CEO of Arjo. January-March 2024 in brief · Net sales increased to SEK 2,759 M (2,638).Net sales grew organically by 4.3%. · Adjusted EBITDA increased 5.7% to SEK 502 M (475). · Adjusted operating profit

Olvi changes the presentation of its segments

Olvi plc     Inside information 18 April 2024 at 3.00 pm   Olvi changes the presentation of its segments   Olvi Group has changed the presentation of the segments to correspond to the monitoring carried out by the management. In future, intra-segment business transactions will be eliminated from the segments’ sales volumes and net sales in their presentation.   The Group’s financial information for 2023 is presented in the tables below, adjusted for the new presentation of the segments. The information disclosed below is unaudited.   Sales volume, L 1,000 1–3/2023

HKScan to change its name - the company’s new name will be HKFoods

Following the sale of HKScan's Swedish business at the end of March 2024, the Annual General Meeting of HKScan held today has decided to change the company name to HKFoods Oyj.The parallel company names of the new name are HKFoods Plc (in English) and HKFoods Abp (in Swedish). “The name HKFoods will continue the company’s traditions and reflects one of the company's core consumer brands, as well as the company's industry and strategic reference. We continue our strategic journey to become a versatile food company. HKFoods is strongly Finnish at its core, but an internationally operating

Resolutions passed by the Annual General Meeting of HKScan Corporation and organization of the Board of Directors

HKScan Corporation, Stock Exchange Release, 18 April 2024, at 2.30 p.m. EESTHKScan Corporation’s Annual General Meeting, held on 18 April 2024 in Turku, adopted the parent company’s and consolidated financial statements, discharged the members and the deputy members of the Board of Directors and the CEO from liability for 2023 and adopted the remuneration report and the remuneration policy for governing bodies. In accordance with the proposals, the AGM decided the following:   Profit distribution The AGM resolved that no dividend will be paid for 2023. Election and remuneration of

Capsol Technologies ASA: Capsol awarded feasibility study for Bioenergy with Carbon Capture and Storage (BECCS) project in Europe

Oslo, Norway – April 18, 2024Capsol Technologies has been awarded a feasibility study for the CapsolEoP®(end-of-pipe) carbon capture technology with a European energy company at one oftheir biomass-fired energy-from-waste (EfW) plants. The study, which will beconducted in Q2 2024, is for a plant aiming to capture 180,000 tons of CO2 perannum.Capsol Technologies aims to make carbon capture technology viable for moreemitters to accelerate the transition to net zero. EfW and biomass are two ofthe company’s key segments, which are often combined as is the case with thisplant.

resolutions at the annual general meeting 2024

At today’s annual general meeting of Akelius Residential Property AB (publ) resolutions were taken to inter alia pay dividends, amend the articles of association, approve the board’s earlier decision to issue class A ordinary shares and to authorize the board to resolve upon new issue of class A ordinary shares. It was hence decided to adopt the profit and loss statement ant the balance sheet as well as the consolidated profit and loss statement and the consolidated balance sheet; in accordance with the proposal of the board to pay dividend to an amount of maximum EUR 0.10 per

Prostatype Genomics announces very strong interim results from long-term follow-up study with Prostatype® in Uppsala

Prostatype Genomics AB ("Prostatype Genomics" or the "Company") announces that interim results from 180 of a total of approximately 500 patients in the ongoing long-term follow-up study at Akademiska University Hospital in Uppsala, Sweden, with the Company's genetic test Prostatype® show excellent accuracy for Prostatype® even after 20 years of follow-up time after diagnosis. None of the analysed patients classified as low risk by Prostatype® died from their prostate cancer during 20 years of follow-up time. The interim results from the Uppsala study, together with data from the ongoing US

Olvi plc: Notification of Managers’ Transactions

Olvi plc                              Stock Exchange Release 18 April 2024 at 2.00 pm Olvi plc: Notification of Managers’ Transactions Person subject to the notification requirementName: Akkel PeepPosition: Other senior managerIssuerName: Olvi plcLEI: 7437003NX7WWVRT6AJ55Initial notificationReference number: 58735/5/4 Transaction detailsTransaction date: 16.4.2024Venue: Outside a trading venueNature of transaction: Receipt of a share-based incentiveInstrument: ShareISIN: FI0009900401Volume: 350 Unit price: 0 EUR Aggregated transactionsVolume: 350

Olvi plc: Notification of Managers’ Transactions

Olvi plc                              Stock Exchange Release 18 April 2024 at 2.00 pm Olvi plc: Notification of Managers’ Transactions Person subject to the notification requirementName: Rissanen MarjattaPosition: Other senior managerIssuerName: Olvi plcLEI: 7437003NX7WWVRT6AJ55Initial notificationReference number: 58726/4/4 Transaction detailsTransaction date: 16.4.2024Venue: Outside a trading venueNature of transaction: Receipt of a share-based incentiveInstrument: ShareISIN: FI0009900401Volume: 650 Unit price: 0 EUR Aggregated transactionsVolume:

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.“We were pleased to share additional analyses from the 2-year Phase 3 NeflgArd trial of Nefecon in IgAN at this year’s World Congress of Nephrology,” said Richard Philipson, Chief Medical Officer of Calliditas. “

BioStock: Annexin towards completion of phase II study and share issue

After reporting promising efficacy signals in the ongoing phase II study on patients with the eye disease RVO, Annexin Pharmaceuticals now has a stronger position in licensing and partnership discussions. To finance continued activities, the company also plans to conduct a rights issue of approximately SEK 45 million, with parts of both the board and management intending to participate. BioStock reached out to CEO Anders Haegerstrand for a comment.Read the interview with CEO Anders Haegerstrand here: https://www.biostock.se/en/2024/04/annexin-towards-completion-of-phase-ii-study-and-

There are no items matching the current filter
There are no more items matching the current filter
Back to top